Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.

Lupi, Alessandro; Bona, Roberta Della; Meliga, Emanuele; Capodanno, Davide; Schaffer, Alon; Bongo, Angelo S; Gaudio, Giovanni; Guasti, Luigina; Alexopoulos, Dimitrios; Valgimigli, Marco; Porto, Italo (2018). Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. Thrombosis and haemostasis, 118(5), pp. 852-863. Schattauer 10.1055/s-0038-1635578

Text 2018 Thromb Haemost_Lupi.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (297kB)

BACKGROUND

Early escalation from clopidogrel to new generation P2Y12 inhibitors is common practice in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Real-world data about this strategy, however, are limited.

METHODS

From 2012 to 2015, 1,057 consecutive STEMI patients treated with pPCI in an Italian hub-and-spoke network were prospectively included in an observational registry (RENOVAMI, ClinicalTrials.gov Identifier: NCT01760382). We compared the prevalence, predictive factors and in-hospital outcomes of patients escalated to a new generation P2Y12 inhibitor within the first 24 hours from pPCI with those continuing on admission antiplatelet therapy.

RESULTS

In the first 24 hours after pPCI, 165 patients (15.6%) were escalated from clopidogrel to a new generation P2Y12 inhibitor, while de-escalation to clopidogrel was occasional (19 patients, 1.8%) and switch between new generation P2Y12 inhibitors was rare (8 patients, 0.8%, all from ticagrelor to prasugrel). Drug eluting stent use (adjusted odds ratio [OR], 2.19, 95% confidence interval [CI], 1.55-3.08,  = 0.0002) and impaired renal function (adjusted OR, 0.19, 95% CI, 0.05-0.77,  = 0.02) were the only independent predictive factors for the decision to escalate. After adjustment for potential confounders, escalation did not predict in-hospital outcomes, whereas the overall use of new generation P2Y12 inhibitors was correlated with a better in-hospital survival (adjusted hazard ratio, 0.47, 95% CI, 0.25-0.91,  = 0.03). Moreover, escalation did not influence bleeding rates.

CONCLUSIONS

In this prospective registry of STEMI patients treated with pPCI and contemporary antiplatelet therapy, early escalation to a new generation P2Y12 inhibitor appeared safe and did not significantly affect in-hospital bleeding rates.

Interest & Impact

Downloads

1 since deposited on 03 Aug 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item